Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Hydrochloride Liposome in Advanced Solid Tumors
NCT04719065Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2021
- Primary completion
- Apr 2022
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in solid tumor (advanced stage) (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Adverse Events up to 36 weeks. Status: unknown.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04719065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04719065.